DAPK2 (Death-Associated Protein Kinase 2)
A serine/threonine kinase involved in apoptosis, autophagy, and tumor suppression.
Gene Information Card
| Symbol | DAPK2 |
|---|---|
| Full Name | Death Associated Protein Kinase 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 15q22.31 |
| NCBI Gene ID | 23604 ncbi.nlm.nih.gov/gene/23604 |
| Ensembl ID | ENSG00000135679 |
| UniProt ID | Q9UIK4 |
| OMIM ID | 605852 |
| HGNC ID | 2674 |
| Aliases | DAP-kinase-related protein 1, DRP-1, DAP kinase 2 |
Description
DAPK2 (Death-Associated Protein Kinase 2) is a member of the death-associated protein kinase (DAPK) family of serine/threonine kinases. It functions as a positive mediator of apoptosis and autophagy, and is implicated in tumor suppression. The gene is located on chromosome 15q22.31 and encodes a 370-amino acid protein. DAPK2 is regulated by calcium/calmodulin and is involved in various cellular processes including cell death, cytoskeletal reorganization, and immune response.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Acute Myeloid Leukemia (AML) | DAPK2 promoter hypermethylation leads to transcriptional silencing, contributing to leukemogenesis. | PMID: 19029989 |
| Bladder Cancer | Reduced DAPK2 expression due to promoter methylation is associated with tumor progression. | PMID: 15944777 |
| Lung Cancer | Loss of DAPK2 expression via methylation promotes cell survival and metastasis. | PMID: 14676830 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lymph node | 21.3 | Medium |
| Spleen | 18.7 | Medium |
| Bone marrow | 15.2 | Medium |
| Lung | 4.1 | Low |
| Brain | 1.2 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (leukemia) | 22.5 | High expression |
| HEK 293 (embryonic kidney) | 8.3 | Moderate expression |
| A549 (lung carcinoma) | 3.1 | Low expression |
| MCF7 (breast cancer) | 1.8 | Not detected |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | Missense | <0.01% | Likely loss of function; start codon loss |
| c.104C>T (p.Pro35Leu) | Missense | <0.01% | Unknown significance |
| c.370G>A (p.Glu124Lys) | Missense | <0.01% | Unknown significance |
Mutation functional classification
Loss of Function (LOF)
Promoter hypermethylation is the primary mechanism of DAPK2 silencing in cancer, leading to loss of pro-apoptotic function.
Gain of Function (GOF)
No gain-of-function mutations have been reported for DAPK2.
Dominant Negative (DN)
No dominant-negative mutations have been characterized for DAPK2.
View complete mutation data：
Gene Ontology (GO)
| • apoptotic process | • protein serine/threonine kinase activity |
| • calmodulin binding | • autophagy |
| • positive regulation of apoptotic process | • cytoskeleton organization |
Pathways
• Apoptosis
• Autophagy
• p53 signaling pathway
Protein Summary
DAPK2 is a 370-amino acid serine/threonine kinase containing a catalytic domain, a calmodulin-binding domain, and a death domain. It is activated by calcium/calmodulin binding and phosphorylates substrates involved in apoptosis and autophagy. DAPK2 is widely expressed in hematopoietic tissues and is frequently silenced by promoter methylation in various cancers, suggesting a tumor suppressor role.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DAPK2 Knockout HEK293 Cell Line | EDJ-KQ8090 | Human | 23604 | Details Get a Quote |
| DAPK2 Knockout A-549 Cell Line | EDJ-KQ33940 | Human | 23604 | Details Get a Quote |
| DAPK2 Knockout HCT 116 Cell Line | EDJ-KQ33941 | Human | 23604 | Details Get a Quote |
| DAPK2 Knockout HeLa Cell Line | EDJ-KQ33942 | Human | 23604 | Details Get a Quote |
